RAZADYNE
LOE ApproachingNDAORALTABLET
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RAZADYNE by Johnson & Johnson is clinical pharmacology mechanism of action although the etiology of cognitive impairment in alzheimer's disease (ad) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with alzheimer's disease. Approved for mild to moderate dementia of the alzheimer's type. First approved in 2001.
Drug data last refreshed 2d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss…
Worked on RAZADYNE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.